TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03178864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Rivaroxaban 20 mg daily (15 mg daily in participants with a CrCl 30-49 mL/min as per the Cockroft-Gault equation)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Accepted standard of care as per American Heart Association/American Stroke Association Guidelines (initial use of unfractionated heparin or low-molecular weight heparin with transition to an oral vitamin K antagonist or continuation with low-molecular weight heparin) with choice of agent at the treating physician's discretion.
Study: NCT04189211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT8001
Description: IV infusions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT8001
Description: IV infusions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT8001
Description: IV infusions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT8001
Description: IV infusions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT8001
Description: IV infusions.
Study: NCT06336850

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Ultrasound-Guided Portal Pressure Gradient Measurement
Description: The endoscopic ultrasound (EUS)-guided 25G fine needle aspirate (FNA) needle procedure is a straightforward minimally invasive technique for direct portal pressure measurements.
Study: NCT04037605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketoconazole Pill (also known as nizoral)
Description: Ketoconazole pill is taken 4 times per inpatient visit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganirelix
Description: Ganirelix subcutaneous injection is administered twice per inpatient visit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganirelix
Description: Ganirelix subcutaneous injection is administered twice per inpatient visit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone Pill
Description: Dexamethasone pills is taken twice per inpatient visit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone injection
Description: Dexamethasone IV injection is given twice per inpatient visit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cosyntropin Injectable Product
Description: Cosyntropin injection is given twice per inpatient visit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Luteinizing Hormone (also known as luveris)
Description: Recombinant Human Luteinizing Hormone is given as 6 IV infusion pulses per inpatient visit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone Injection (also known as solu-cortef)
Description: Hydrocortisone IV push is given twice per inpatient visit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonadorelin (also known as Lutrepulse)
Description: Gonadorelin IV injection is given twice per inpatient visit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonadorelin (also known as Lutrepulse)
Description: Gonadorelin IV injection is given twice per inpatient visit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonadorelin (also known as Lutrepulse)
Description: Gonadorelin IV injection is given twice per inpatient visit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonadorelin (also known as Lutrepulse)
Description: Gonadorelin IV injection is given twice per inpatient visit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticorelin (also known as Acthrel)
Description: Corticorelin IV injection is given twice per inpatient visit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticorelin (also known as Acthrel)
Description: Corticorelin IV injection is given twice per inpatient visit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticorelin (also known as Acthrel)
Description: Corticorelin IV injection is given twice per inpatient visit
Study: NCT03387995

Intervention type: DEVICE
Intervention: Enterprise stent
Description: The paitents treated by Enterprise stent implantation.

Intervention type: DEVICE
Intervention: Neuroform stent
Description: The paitents treated by Neuroform stent implantation.

Intervention type: DEVICE
Intervention: Neuroform stent
Description: The paitents treated by Neuroform stent implantation.

Intervention type: DEVICE
Intervention: Neuroform stent
Description: The paitents treated by Neuroform stent implantation.

Intervention type: DEVICE
Intervention: Neuroform stent
Description: The paitents treated by Neuroform stent implantation.
Study: NCT04037605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticorelin (also known as Acthrel)
Description: Corticorelin IV injection is given twice per inpatient visit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral tablet
Description: Placebo for Ketoconazole are given 4 times per inpatient visit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo oral tablet
Description: Placebo for Ketoconazole are given 4 times per inpatient visit
Study: NCT03387995

Intervention type: DEVICE
Intervention: Neuroform stent
Description: The paitents treated by Neuroform stent implantation.
Study: NCT04037605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline Solution
Description: Saline Solution (Placebo) for Dexamethasone IV injection or hydrocortisone IV injection given up to four times per inpatient visit
Study: NCT03387995

Intervention type: DEVICE
Intervention: Flow diverter (FD) stent
Description: The paitents treated by Enterprise FD implantation.

Intervention type: DEVICE
Intervention: Flow diverter (FD) stent
Description: The paitents treated by Enterprise FD implantation.

Intervention type: DEVICE
Intervention: Flow diverter (FD) stent
Description: The paitents treated by Enterprise FD implantation.

Intervention type: DEVICE
Intervention: Flow diverter (FD) stent
Description: The paitents treated by Enterprise FD implantation.

Intervention type: DEVICE
Intervention: Flow diverter (FD) stent
Description: The paitents treated by Enterprise FD implantation.
Study: NCT04037605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline Solution
Description: Saline Solution (Placebo) for Dexamethasone IV injection or hydrocortisone IV injection given up to four times per inpatient visit

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline solution for injection
Description: Saline Solution (placebo) for ganirelix subcutaneous injection
Study: NCT02281786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to RO6926496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to RO6926496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to RO6926496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to RO6926496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to RO6926496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo to RO6926496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6926496
Description: single, ascending dose, intravenous administration
Study: NCT04037605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline solution for injection
Description: Saline Solution (placebo) for ganirelix subcutaneous injection
Study: NCT02889484

Intervention type: PROCEDURE
Intervention: Lumbar disc hernia surgery

Intervention type: PROCEDURE
Intervention: Lumbar disc hernia surgery

Intervention type: PROCEDURE
Intervention: Lumbar disc hernia surgery
Study: NCT02964351

Intervention type: BIOLOGICAL
Intervention: High PSA levels
Study: NCT01602874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tigecycline
Description: Subject with cIAI:~Dosing information for subjects 8 to 11 years old is currently under investigation and will be determined later. Subjects 12 to 17 years old will receive tigecycline 50 mg IV every 12 hours, metronidazole placebo IV will be administered every 8 hours. In addition, at the discretion of the investigator, an aminoglycoside placebo IV may also be administered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tigecycline
Description: Subject with CAP:~IV therapy period: Dosing information for subjects 8 to 11 years old is currently under investigation and will be determined later. Subjects 12 to 17 years old will receive tigecycline 50 mg IV every 12h. At the discretion of the investigator oral clarithromycin placebo may be given every 12h.~Oral therapy period: If oral switch criteria are met, on or after Day 4 amoxicillin/clavulanate may be prescribed (40 mg/kg per day divided into 3 equal doses, maximum of 500 mg/dose to subjects weighing less than 40 kg and 500 mg every 8h to subjects weighing 40 kg or greater). In addition, if oral clarithromycin or placebo had been given during the IV period, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside
Description: Subject with cIAI:~Subjects will receive ceftriaxone 35 mg/kg (maximum of 1 g/dose) IV every 12 hours, metronidazole 10 mg/kg (maximum of 1 g/dose) IV will be administered every 8 hours.~In addition, at the discretion of the investigator, an aminoglycoside IV (adjusted dose if necessary) may also be given.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CAP: Ceftriaxone, plus if applicable oral clarithromycin
Description: Subject with CAP:~IV therapy period: Subjects will receive ceftriaxone 35 mg/kg (maximum of 1 g/dose) IV every 12h. At the discretion of the investigator, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old).~Oral therapy period: If oral switch criteria are met, on or after Day 4 amoxicillin/clavulanate may be prescribed (40 mg/kg per day divided into 3 equal doses, maximum of 500 mg/dose to subjects weighing less than 40 kg and 500 mg every 8h to subjects weighing 40 kg or greater). In addition, if oral clarithromycin or placebo had been given during the IV period, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old).
Study: NCT04566211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: (panto+amox+clar+metr)+(panto+amox)
Description: a 7-day quadruple regimen with pantoprazole 40 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 3-day dual regimen with pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pantoprazole+bismuth+amox+clar
Description: pantoprazole 40 mg twice daily, bismuth subcitrate 240 mg twice daily, and amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily for 10 days
Study: NCT02938871

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Synbiotic
Description: The patients of this group will receive 6 grams of synbiotic composition, to be administered via feeding tube or orally, twice time a day, for 15 consecutive days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The patients of this group will receive 6 grams of maltodextrin, to be administered via feeding tube or orally, twice time a day, for 15 consecutive days.
Study: NCT04774107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P1101 + Ribavirin
Description: P1101 400 µg SC
Study: NCT02281786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6926496
Description: single, ascending dose, intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6926496
Description: single, ascending dose, intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6926496
Description: single, ascending dose, intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6926496
Description: single, ascending dose, intravenous administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO6926496
Description: single, ascending dose, intravenous administration
Study: NCT03638531

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Description: Anodal tDCS will be applied over the FDI muscle representational area of the motor cortex for 25 minutes in combination with the two motor tasks (precision grip task and handwriting task).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM tDCS
Description: SHAM tDCS will be applied over the FDI muscle representational area of the motor cortex for 25 minutes in combination with the two motor tasks (precision grip task and handwriting task).
Study: NCT00422149

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SUBLIVAC® Grasses/Placebo treatment
Description: SUBLIVAC® Grasses/Placebo treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SUBLIVAC® Grasses/Placebo treatment
Description: SUBLIVAC® Grasses/Placebo treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SUBLIVAC® Grasses treatment
Description: SUBLIVAC® Grasses treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment
Description: Placebo treatment
Study: NCT04418011

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: The present study aims to use both repetitive transcranial magnetic stimulation (rTMS) and intermittent theta burst stimulation (iTBS), safe and effective forms of neuromodulation, to target the neural circuitry of social cognitive (SCog) impairments in people with SSDs. Treatment sessions will be administered five days per week for two weeks.~Other Name: MagPro X100 or R30 (Medtronic A/S. Copenhagen, Denmark) equipped with a Cool-B70 A/P coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark), positioned under MRI guidance using the Brainsight neuronavigation system (Rogue Resolutions, Montreal, Canada) or Localite (Localite GmbH, Bonn, Germany)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation (Intermittent Theta Burst Stimulation)
Description: The present study aims to use both repetitive transcranial magnetic stimulation (rTMS) and intermittent theta burst stimulation (iTBS), safe and effective forms of neuromodulation, to target the neural circuitry of social cognitive (SCog) impairments in people with SSDs. Treatment sessions will be administered five days per week for two weeks.~Other Name: MagPro X100 or R30 (Medtronic A/S. Copenhagen, Denmark) equipped with a Cool-B70 A/P coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark), positioned under MRI guidance using the Brainsight neuronavigation system (Rogue Resolutions, Montreal, Canada) or Localite (Localite GmbH, Bonn, Germany)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation (Sham)
Description: Other Name: MagPro X100 or R30(Medtronic A/S. Copenhagen, Denmark) equipped with a Cool-B70 A/P coil and Qooler fluid-cooling device (MagVenture, Farum, Denmark), positioned under MRI guidance using the Brainsight neuronavigation system (Rogue Resolutions, Montreal, Canada) or Localite (Localite GmbH, Bonn, Germany)
Study: NCT03548506

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Omnidirectional Deep Brain Stimulation of STN
Description: Deep Brain Stimulation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Directional Deep Brain Stimulation of STN
Description: Deep Brain Stimulation
Study: NCT00842946

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure w/ Acceptance-Based Rationale
Description: Treatment focuses on the ineffectiveness of participants' past attempts to control or reduce their anxiety in public speaking situations. Acceptance of one's private experiences (thoughts, feelings, sensations) will be introduced. Willingness to experience unwanted thoughts and feelings while simultaneously engaging in valued activities, especially those related to public speaking, is stressed. Techniques designed to foster psychological acceptance are practiced prior to and during exposure exercises, as well as assigned for homework between sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure w/ Habituation-Based Rationale
Description: Exposure to feared public speaking situations are accompanied by explanations of behavioral principles, including classical/operant conditioning and habituation. The process of associating public speaking situations with unwanted feelings of anxiety will be discussed, as well as negative reinforcement of escape and avoidance behaviors. The underlying principle of habituation is reviewed. When engaging in exposure exercises (both in session and assigned homework exercises), participants will be encouraged to remain in the feared speaking situation until their subjective ratings of anxiety decrease.
Study: NCT04319380

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tetanus/diphtheria toxoids
Description: One dose of tetanus/diphtheria toxoids vaccine (June) in year 1 and year 2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SMC with SP+AQ
Description: Year 1 and 2 (2020/21) Four cycles of SMC (SP+AQ) (July, August, September, October). One cycle of SMC consisting of sulphadoxine - pyrimethamine (SP) 500mg/25 mg, and amodiaquine (AQ) 150mg on day 1, and AQ 150mg on days 2 and 3.
Study: NCT03199586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NP-G2-044
Description: capsule
Study: NCT00856284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin
Description: Alogliptin tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glipizide
Description: Glipizide tablets
Study: NCT04537767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol
Description: The protocol required a titrated esmolol infusion commenced at 25 mg/ h, with an upper dose limit of 2000 mg/h, to maintain the HR between 75 and 90 bpm in ES group. The control group were treated with placebo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00536601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV
Study: NCT04319380

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SMC with SP+AQ
Description: Year 1 and 2 (2020/21) Four cycles of SMC (SP+AQ) (July, August, September, October). One cycle of SMC consisting of sulphadoxine - pyrimethamine (SP) 500mg/25 mg, and amodiaquine (AQ) 150mg on day 1, and AQ 150mg on days 2 and 3.
Study: NCT00536601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carmustine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: busulfan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiotepa
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thiotepa
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Description: Undergo TBI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation
Description: Undergo ASCT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation
Description: Undergo ASCT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation
Description: Undergo ASCT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation
Description: Undergo ASCT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous hematopoietic stem cell transplantation
Description: Undergo ASCT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous-autologous tandem hematopoietic stem cell transplantation
Description: Undergo tandem ASCT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous-autologous tandem hematopoietic stem cell transplantation
Description: Undergo tandem ASCT
Study: NCT01327885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin mesylate 1.4 mg/m^2 intravenous
Description: Administration of eribulin mesylate at a dose of 1.4 mg/m\^2 as an intravenous (IV) bolus infusion over 2-5 minutes on Days 1 and 8 of every cycle, where the duration of each cycle is 21 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IV
Description: Administration of dacarbazine at a dose of 850 mg/m\^2, or 1,000 mg/m\^2, or 1,200 mg/m\^2 selected by the Principal Investigator \[PI\] or designee according to the subject's clinical status as an IV infusion over 15-30 minutes on Day 1 of every cycle, where the duration of each cycle is 21 days.